Why 6 strains?
The beneficial effects of probiotics are both strain- and dose-specific. A combination of various probiotic strains working together has been
shown to be the most effective in the gut7. In addition, more significant results can be achieved with multiple strains in combination compared to single strain preparations8.
Scheduling status: S0. Proprietary name (and dosage form): PROBILIFT D (capsules). Pharmacological classification: D. 34.12 Multiple Substance Formulation. Complementary Medicines. Health Supplement. Pharmacological action: Probiotics are beneficial bacteria, essential for improving intestinal health. Babies are born without any microflora and are thus more susceptible to opportunistic gut conditions. PROBILIFT D is a probiotic supplement specially formulated with 6 probiotic strains and vitamin D. By supplementing your baby’s diet with PROBILIFT D, you can strengthen the barrier effect in the intestines to keep them healthy. Probiotics can increase the levels of beneficial bacteria in the gut, creating an environment that is unfavourable to the growth of harmful bacteria. By introducing live probiotic cultures to the intestinal tract, the beneficial gut flora populations are increased and transitory flora, including pathogenic or bad bacteria, are not able to colonise the intestine. The addition of vitamin D may help with the development of healthy bones and teeth and may contribute to the normal function of the immune system. PROBILIFT D has been specially formulated for babies. When ingested on a regular basis, probiotics should improve or normalise the microbial balance in the human intestines and thereby improve the functioning of the digestive tract. Identification: PROBILIFT D contains a cream coloured liquid with white suspended particles. Presentation PROBILIFT D is packed in a 30 ml amber glass bottle containing 30 ml of liquid, with a black plastic tamper evident cap and graduated glass pipette. Agera Health. firstname.lastname@example.org . www.agerahealth.co.za . 30 ml.
- Binns, N. (2013) Probiotics, Prebiotics and the Gut Microbiota. ILSI Europe Concise Monograph Series.
- Lutgendorff, F., Akkermans, L. M., Söderholm, J. D. (2008). The role of microbiota and probiotics in stress-induced gastrointestinal damage. Current Molecular Medicine, 8, 282-98.
- Fooks, L. J., Fuller, R., Gibson, G. R. (1999). Prebiotics, probiotics and human gut microbiology. International Dairy Journal, 9, 53-61.
- Kyne, L., Kelly, C. P. (2001). Recurrent Clostridium difficile diarrhoea. Gut, 49, 152–153.
- Sazawal, S., Hiremath, G., Dhingra, U., Malik, P., Deb, S, Black, R. E. (2006). Efficacy of probiotics in prevention of acute diarrhoea: a meta-analysis of masked, randomised, placebo-controlled trials. The Lancet Infectious Diseases, 6(6), 374 –382.
- Guandalini, S. (2006). Probiotics for children: use in diarrhea. Journal of Clinical Gastroenterology, 40(3), 244–248.
- Timmerman, H. M., Koning, C. J., Mulder, L., Rombouts, F. M., Beynen, A. C. (2004). Monostrain, multistrain and multispecies probiotics: a comparison of functionality and efficacy. International Journal of Food Microbiology, 96(3), 219-233.
- Leyer, G. J., Li, S., Mubasher, M. E., Reifer, C., Arthur C. Ouwehand, A. C. (2009). Probiotic Effects on Cold and Influenza-Like Symptom Incidence and Duration in Children. Pediatrics, 124, 172-179.
- Ringel, Y., Ringel-Kulka, T., Maier, D., Carroll, I., Galanko, J. A., Leyer, G., Palsson, O. S. (2011). Clinical trial: Probiotic Bacteria Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 Versus Placebo for the Symptoms of Bloating in Patients with Functional Bowel Disorders – a Double-Blind Study. Journal of Clinical Gastroenterology, 45(6), 518–525.
- Van der Kleij, H., O’Mahony, C., Shanahan, F., O’Mahony, L., Bienenstock, J. (2008). Protective effects of Lactobacillus reuteri and Bifidobacterium infantis in murine models for colitis do not involve the vagus nerve. American Journal of Physiology- Regulatory, Integrative & Comparative Physiology, 295, 1131–1137.
- Rautava, S., Kalliomaki, M., Isolauri, E. (2005). New therapeutic strategy for combating the increasing burden of allergic disease: probiotics: a Nutrition, Allergy, Mucosal Immunology and Intestinal Microbiota (NAMI) Research Group report. Journal of Allergy & Clinical Immunology, 116(1), 31–37.